Canhelp Genomics
Canhelp Genomics develops clinically validated molecular diagnostics to detect cancer early and guide personalized treatment. It combines proprietary RNA profiling assays with AI/ML models and digital pathology to deliver tests including the pan-cancer Canhelp‑Origin, an MSI deep‑learning detector, and urine RNA liquid biopsies (UCa and a PCa pipeline). The company sells primarily to hospitals, clinical labs, and pathology centers as a B2B precision oncology diagnostics provider and offers regulatory‑cleared assays (NMPA and CE‑IVD) integrated into clinical workflows. Canhelp maintains ISO‑13485‑certified GMP facilities and an AI research center, holds 50+ patents, and has published pivotal clinical evidence including a randomized Phase 3 trial in The Lancet Oncology, supporting scalable commercial testing and pipeline expansion.
Canhelp Genomics
Canhelp Genomics develops clinically validated molecular diagnostics to detect cancer early and guide personalized treatment. It combines proprietary RNA profiling assays with AI/ML models and digital pathology to deliver tests including the pan-cancer Canhelp‑Origin, an MSI deep‑learning detector, and urine RNA liquid biopsies (UCa and a PCa pipeline). The company sells primarily to hospitals, clinical labs, and pathology centers as a B2B precision oncology diagnostics provider and offers regulatory‑cleared assays (NMPA and CE‑IVD) integrated into clinical workflows. Canhelp maintains ISO‑13485‑certified GMP facilities and an AI research center, holds 50+ patents, and has published pivotal clinical evidence including a randomized Phase 3 trial in The Lancet Oncology, supporting scalable commercial testing and pipeline expansion.